<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="700">
  <stage>Registered</stage>
  <submitdate>7/09/2005</submitdate>
  <approvaldate>7/09/2005</approvaldate>
  <nctid>NCT00151463</nctid>
  <trial_identification>
    <studytitle>QEQ Treatment Responsiveness Evaluation Study</studytitle>
    <scientifictitle>An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A1481195</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Impotence</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - sildenafil citrate

Treatment: drugs: sildenafil citrate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment response to the Quality of Erection Questionnaire (QEQ) after treatment with Viagra in men with erectile dysfunction</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to week 6 of the QEQ total score</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to week 6 in the 5 IIEF domain scores</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in scores of QEQ individual question</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects must have documented clinical diagnosis of erectile dysfunction based on a
             screening SHI-M score of &lt;21 and the subject fulfilling the NIH definition of erectile
             dysfunction

          -  Subjects must be either PDE-5 inhibitor naive; i.e. have never used sildenafil,
             tadalafil or vardenafil, or have been previously treated with no more than six doses
             of a PDE-5 inhibitor (sildenafil, tadalafil, vardenafil) and must have taken their
             last dose no less than 4 weeks prior to the screening visit</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects who are currently prescribed, taking and/or likely to be treated with
             nitrates or nitric oxide donors in any form on either a regular or intermittent basis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Pfizer Investigational Site - Bondi Junction</hospital>
    <hospital>Pfizer Investigational Site - Darlinghurst</hospital>
    <hospital>Pfizer Investigational Site - St Leonards</hospital>
    <hospital>Pfizer Investigational Site - Spring Hill</hospital>
    <hospital>Pfizer Investigational Site - Adelaide</hospital>
    <hospital>Pfizer Investigational Site - Clayton</hospital>
    <hospital>Pfizer Investigational Site - Malvern</hospital>
    <hospital>Pfizer Investigational Site - Mentone</hospital>
    <hospital>Pfizer Investigational Site - Nedlands</hospital>
    <postcode> - Bondi Junction</postcode>
    <postcode> - Darlinghurst</postcode>
    <postcode> - St Leonards</postcode>
    <postcode> - Spring Hill</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Malvern</postcode>
    <postcode> - Mentone</postcode>
    <postcode> - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The Quality of Erection Questionnaire (QEQ) is a new questionnaire that was developed to
      assess erectile attributes in men with erectile dysfunction. The study objective is to
      validate the Quality of Erection Questionnaire (QEQ) through the evaluation of subject
      responses to the QEQ regarding the quality and hardness of erections at baseline compared to
      subject responses post 6 and 10 weeks dosing with Viagra (sildenafil citrate).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00151463</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>